Literature DB >> 18665906

In vitro effect of cyclosporin A on primary and chronic BK polyoma virus infection in Vero E6 cells.

P D Acott1, P A O'Regan, S H Lee, J F S Crocker.   

Abstract

Cyclosporin A (CsA) is known to possess antiviral activity against several viruses in vitro, but the effect of CsA on BK polyoma virus (BKV) replication has not been examined. We investigated the impact of CsA on primary, chronic, and high-level BKV infection using a cell system of kidney cell origin (Vero E6 cells). During the first 2 h post infection, cells treated with CsA up to 3200 microg/L showed a near-identical BK viral load to untreated cells, with only a very minor reduction in the CsA-treated cells observed at 4 h. In chronic culture, CsA completely suppressed the primary BKV infection peak in a non-dose-dependent manner within the dose range of 200-12,800 microg/L (P<0.05). BKV reactivation was also inhibited in the presence of CsA at doses of 200-3200 microg/L: the mean number of BKV DNA copies/mL remained stable or even decreased slightly compared with a 7-log increase in the non-CsA group (P<0.01). CsA did not influence BKV DNA copies/mL in Vero E6 cells with high-level infection (>10(9) copies/mL). Cellular protein measurements indicated that the antiviral effect of CsA was not a result of cytotoxicity. These findings from a relevant in vitro kidney cell system indicate that CsA suppresses the primary BKV infection peak and inhibits escape to BKV reactivation; these effects are dose independent and not related to cytotoxicity. The intracellular antiviral mode of action of CsA against BKV does not appear to be via inhibition of viral cell entry pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18665906     DOI: 10.1111/j.1399-3062.2008.00330.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  14 in total

1.  Transplantation: Immunosuppression and risk of polyomavirus BK replication.

Authors:  Phuong-Thu T Pham; Uttam G Reddy
Journal:  Nat Rev Nephrol       Date:  2013-02-12       Impact factor: 28.314

Review 2.  Post-transplantation malignancies: here today, gone tomorrow?

Authors:  Edward K Geissler
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

3.  The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.

Authors:  A Rimondo; R Crocchiolo; J El-Cheikh; S Bramanti; A Granata; S Furst; B Sarina; L Morabito; R Devillier; S Harbi; B Mohty; R Mineri; C Faucher; C Chabannon; A Santoro; D Blaise; L Castagna
Journal:  Bone Marrow Transplant       Date:  2016-07-18       Impact factor: 5.483

Review 4.  Management of polyomavirus-associated nephropathy in renal transplant recipients.

Authors:  Dirk R J Kuypers
Journal:  Nat Rev Nephrol       Date:  2012-04-17       Impact factor: 28.314

5.  Infection rates in tacrolimus versus cyclosporine-treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1-year analysis.

Authors:  Sarah J Kizilbash; Michelle N Rheault; Ananta Bangdiwala; Arthur Matas; Srinath Chinnakotla; Blanche M Chavers
Journal:  Pediatr Transplant       Date:  2017-03-31

6.  BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression.

Authors:  Katherine A Barraclough; Nicole M Isbel; Christine E Staatz; David W Johnson
Journal:  J Transplant       Date:  2011-06-02

7.  A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients.

Authors:  Lilli Gard; Willem van Doesum; Hubert G M Niesters; Willem J van Son; Arjan Diepstra; Coen A Stegeman; Henk Groen; Annelies Riezebos-Brilman; Jan Stephan Sanders
Journal:  PLoS One       Date:  2017-06-13       Impact factor: 3.240

8.  Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study.

Authors:  H H Hirsch; F Vincenti; S Friman; M Tuncer; F Citterio; A Wiecek; E H Scheuermann; M Klinger; G Russ; M D Pescovitz; H Prestele
Journal:  Am J Transplant       Date:  2012-11-08       Impact factor: 8.086

Review 9.  Lipid, blood pressure and kidney update 2013.

Authors:  Maciej Banach; Corina Serban; Wilbert S Aronow; Jacek Rysz; Simona Dragan; Edgar V Lerma; Mugurel Apetrii; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2014-02-27       Impact factor: 2.370

10.  BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12.

Authors:  H H Hirsch; K Yakhontova; M Lu; J Manzetti
Journal:  Am J Transplant       Date:  2015-12-07       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.